Lawmakers press genetic testing companies for details on their privacy policies
By Megan Thielking,
Stat News
| 06. 21. 2018
Pressure is growing on direct-to-consumer genealogy and genetic testing companies to be more transparent about their privacy policies, after the arrest of the notorious Golden State Killer using publicly available data from one of the websites.
In a letter sent this week — and shared with STAT — Reps. Dave Loebsack of Iowa and Frank Pallone Jr. of New Jersey peppered four of the platforms with questions about their security systems and customer privacy. The Democratic lawmakers are hoping to work with the companies — 23andMe, AncestryDNA, Family Tree DNA, and National Geographic Geno — to identify and resolve any privacy and security issues. And they’re in a prime position to do so: They sit on the Energy and Commerce committee, which handles both health care and privacy issues in technology.
“Much more often than not, Congress acts after the horse is out of the barn,” Loebsack said. “I want to try to partner with genetic testing services to address any potential challenges before there are actually breaches of trust.”
Genetic testing and genealogy platforms have come under fresh scrutiny...
Related Articles
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Stephanie Pappas, LiveScience | 01.15.2026
Genetic variants believed to cause blindness in nearly everyone who carries them actually lead to vision loss less than 30% of the time, new research finds.
The study challenges the concept of Mendelian diseases, or diseases and disorders attributed to...
By David Cox, Wired | 01.05.2026
As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea.
The gene-editing technology Crispr is best known for delivering groundbreaking new therapies for rare diseases, tweaking...
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...